Department of Oncology, IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Canton Ticino, Switzerland; Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Piedmont, Italy.
Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Piedmont, Italy.
Clin Genitourin Cancer. 2024 Oct;22(5):102138. doi: 10.1016/j.clgc.2024.102138. Epub 2024 Jun 12.
Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted the efficacy of ADT even in earlier disease settings such as in localized disease or in the case of biochemical recurrence (BCR). Improved knowledge of PC biology and ADT resistance mechanisms have led to the development of novel generation androgen receptor pathway inhibitors (ARPI). Initially used only in patients who became resistant to ADT, ARPI have subsequently shown to be effective when used in patients with metastatic hormone-naive disease and in recent years their effectiveness has also been evaluated in localized disease and in case of BCR. The objective of this review is to describe the current role of agents interfering with the androgen receptor in different stages of PC and to point out future perspectives.
前列腺癌（PC）通常是一种激素依赖性肿瘤。雄激素剥夺疗法（ADT）已经成为转移性疾病的标准治疗方法，超过 80 年。随后的研究强调了 ADT 的疗效，即使在局部疾病或生化复发（BCR）等早期疾病环境中也是如此。对 PC 生物学和 ADT 耐药机制的深入了解导致了新一代雄激素受体通路抑制剂（ARPI）的发展。最初仅用于对 ADT 耐药的患者，ARPI 随后在转移性激素敏感疾病患者中显示出有效性，近年来，其在局部疾病和 BCR 中的有效性也得到了评估。本综述的目的是描述目前干扰雄激素受体在 PC 不同阶段的药物的作用，并指出未来的展望。
